Translatable Models in Neuroscience

Amongst the latest innovations in patient-derived iPSC models, 3D brain organoid models, advances in artificially driving neurodegeneration in vivo, and AI/ML methods to utilize messy biological data, biopharma is prioritizing preclinical models.

Time: 8:00 am – 5:00 pm

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
Drug Developer Pricing – Conference + 1 Workshop: USD 3098.00,
Drug Developer Pricing – Conference Only: USD 2599.00,
Solution Provider Pricing – Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing – Conference Only: USD 3799.00

Speakers: Andrea Peralta, Senior Associate Scientist, Biogen, Beth Hoffman, Chief Executive Officer, Origami Therapeutics, Daria Prilutsky, Associate Director in Computational Biology, Takeda, Fares Bassil, Director, In Vivo Pharmacology, Eli Lilly and Co., Gabriele Proetzel, Senior Director – Neuroscience External Research, Takeda, Iosif Pediaditakis, Associate Director, Alchemab Therapeutics, James Fink, Director – Epilepsy Lead, Quiver Bioscience, Jeremy Huang, Senior Scientist, Sanofi, Julia Maeve, Bonner Principal Scientist, Sanofi, and more.